Clinical Trial Update: Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 pilot trial evaluating a combination of bortezomib, bendamustine, and rituximab in non-Hodgkin lymphoma; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Treanda) (bendamustine)
• Bortezomib (Velcade) (Bortezomib)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: University of Rochester | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2011-06-06